Dyadic International Inc. (NASDAQ: DYAI) reported third-quarter 2026 revenue of $449,101, down 61.4% from $1.16 million a year earlier. Net loss was $1.36 million, or $0.04 per basic and diluted share, compared with a $1.98 million loss, or $0.06 per share, in the prior-year quarter.
The biotechnology company reported its first direct commercial product sales during the quarter, primarily recombinant transferrin and DNase I. It also said Inzymes achieved a first commercial sale of camel chymosin in October, with Dyadic expecting to recognize a $225,000 milestone payment as fourth-quarter revenue.
- Cash, cash equivalents, restricted cash and investment-grade securities including accrued interest totaled $6.05 million as of September 30, 2026, versus $8.59 million at December 31, 2025.
- Research and development expense declined 24.8% to $429,945.
- General and administrative expense declined 2.1% to $1.45 million.
- Loss from operations was $1.81 million, compared with $1.93 million a year earlier.
- Dyadic recorded $455,324 in total other income, net, including a $545,527 non-cash gain from the change in fair value of warrant liability, net of issuance costs.
$DYAI Insider Trading Activity
$DYAI insiders have traded $DYAI stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $DYAI stock by insiders over the last 6 months:
- TRUST UNDER AGREEMENT DATED FEBRUARY 28, 1996 FRANCISCO has made 0 purchases and 3 sales selling 95,392 shares for an estimated $124,957.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$DYAI Hedge Fund Activity
We have seen 12 institutional investors add shares of $DYAI stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- APIS CAPITAL ADVISORS, LLC removed 466,090 shares (-36.7%) from their portfolio in Q2 2026, for an estimated $417,616
- RENAISSANCE TECHNOLOGIES LLC added 79,440 shares (+100.8%) to their portfolio in Q3 2026, for an estimated $35,319
- BLACKROCK, INC. removed 77,676 shares (-28.2%) from their portfolio in Q2 2026, for an estimated $69,597
- LANDSCAPE CAPITAL MANAGEMENT, L.L.C. removed 55,263 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $24,569
- CHAPIN DAVIS, INC. added 55,000 shares (+6.2%) to their portfolio in Q3 2026, for an estimated $24,453
- MARATHON CAPITAL MANAGEMENT added 47,602 shares (+43.3%) to their portfolio in Q3 2026, for an estimated $21,163
- XTX TOPCO LTD added 46,665 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,811
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
